# PT-141 Benefits Reported in Research

> PT-141 benefits reported in research: the measured desire and distress improvements, the central mechanism behind them, and an honest read of how large the effect actually is. Cited.

What the trials actually measured — and how big the effect really is.

## The short version

The PT-141 benefits reported in research are narrow and specific: more sexual desire, less distress about low desire — in one approved group, premenopausal women with HSDD. That is the headline, and it is cited.

The honest qualifier sits right next to it. The effect is statistically real but small [3]. Desire scores rose by a fraction of a point; distress fell by a fraction of a point [3]. Independent re-analyses argue the change, while significant, may be modest in real life [3]. So the benefit is genuine and limited at the same time. The unusual part is the route: this benefit comes from acting on the brain's desire circuitry, not on blood flow [1]. Below, each benefit is tied to its study. No dose is recommended.

## The measured benefit in approved use

In the RECONNECT Phase 3 trials (n=1267 premenopausal women with HSDD), bremelanotide 1.75 mg as-needed met both coprimary endpoints over 24 weeks: desire rose (FSFI-desire +0.35, P<.001) and desire-related distress fell (FSDS-DAO item 13 -0.33, P<.001) versus placebo [3]. The 52-week extension (684 women) showed the desire improvement was sustained with no new safety signals [4]. A 2026 systematic review and meta-analysis pooled the trials and found improvement in total FSFI plus the desire and arousal subscales [15].

## Why the benefit is central, not vascular

The benefit traces to mechanism. MC4R agonism in hypothalamic circuits engages dopaminergic pathways tied to sexual motivation [1]. The 2022 fMRI study made this concrete: in 31 women with HSDD, MC4R agonism increased desire for up to 24 hours and changed how the brain processed erotic stimuli (enhanced amygdala-insula connectivity) [5]. In female rats, PT-141 selectively raised desire-driven solicitational behavior — without touching reflexive behavior [2]. The benefit is a desire benefit, produced in the brain.

## An honest read of the effect size

Benefit framing requires the qualifier. Critical re-analyses argue the trial effects on desire and distress, while statistically significant, are small and question their clinical meaningfulness [3]. Reviews report good evidence for bremelanotide in HSDD while stressing approved options remain few and trial-design limitations apply [8][11]. The benefit is real, cited, and bounded — and it applies to the approved premenopausal-HSDD group [7][10]. Off-label benefit claims (men, postmenopausal, performance) are not approved and rest on early-phase or disputed data [7]. See [PT-141 results](/results).

---

A magenta-circuit terminal reading of the PT-141 (bremelanotide) record — the one approved indication printed first, the label dose and trial figures echoed back verbatim, the off-label and unregulated-research-chemical lines traced in amber, and the community field reports fenced off as unverified; no clinic wired behind the console and nothing here dosed, sourced, prescribed, or sold.